A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data
NCT ID: NCT07156617
Last Updated: 2025-09-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
2000 participants
OBSERVATIONAL
2025-10-01
2028-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma
NCT06542796
Combined Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma
NCT04152356
Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma
NCT06405321
The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy
NCT06746194
Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC
NCT06818097
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Interventional therapy combined with systemic therapy
Interventional therapy combined with systemic therapy is divided into three subgroups, including 1)DEB-TACE in Combination with Targeted Therapy；2） DEB-TACE in Combination with Targeted Therapy and Immunotherapy；3）DEB-TACE in Combination with Targeted Therapy, Immunotherapy, and Other Interventional Therapies.
Interventional therapy
Interventional therapy
Systemic therapy
Targeted Therapy drugs include but are not limited to Lenvatinib, Apatinib, etc. Immunotherapy drugs include but are not limited to Camrelizumab, Tislelizumab
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Interventional therapy
Interventional therapy
Systemic therapy
Targeted Therapy drugs include but are not limited to Lenvatinib, Apatinib, etc. Immunotherapy drugs include but are not limited to Camrelizumab, Tislelizumab
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xuhua Duan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xuhua Duan
The First Affiliated Hospital of Zhengzhou University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Second Affiliated Hospital of Hainan Medical Universsity
Haikou, Hainan, China
Xingtai No.5 Hospital
Xingtai, Hebei, China
Deng zhou People's Hospital
Dengzhou, Henan, China
The Second People's Hospital of Jiaozuo
Jiaozuo, Henan, China
Huai He Hospital of Henan University
Kaifeng, Henan, China
Luo Yang Central Hospital
Luoyang, Henan, China
The First Affiliated Hospital of Henan University of science and Technology
Luoyang, Henan, China
First People's Hospital of Shangqiu
Shangqiu, Henan, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Zhou Kou Central Hospital
Zhoukou, Henan, China
Wuxi No.5 People's Hospital
Wuxi, Jiangsu, China
Jiangxi Provincial People's Hospitail
Nanchang, Jiangxi, China
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Second People's Hospital of Jiaozuo
Jiaozuo, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Yong Wang
Role: primary
Menglong Li
Role: primary
Yanliang Li
Role: primary
Chuntang Qin
Role: primary
Xiang He
Role: primary
Fazhong Li
Role: primary
Zhenhua Tian
Role: primary
Role: backup
Cheng Xing
Role: primary
Shihua Luo
Role: primary
Chuntang Qin
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-KY-1142-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.